PMCB Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 Mai 2024 @ 22:00):

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States...

Stats
Tagesvolumen	3 445.00
Durchschnittsvolumen	25 772.00
Marktkapitalisierung	17.86M
EPS	$0 ( 2024-03-15 )
Nächstes Ertragsdatum	( $0 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.430
ATR14	$0.0260 (1.20%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-20	Weinstein Robert	Buy	61 248	Stock Option (Right to Buy)
2023-11-20	Walker Wayne Remell	Buy	61 248	Stock Option (Right to Buy)
2023-11-20	Trujillo Carlos	Buy	85 000	Stock Option (Right to Buy)
2023-11-20	Silverman Joshua	Buy	170 000	Stock Option (Right to Buy)
2023-11-20	Schechter Jonathan	Buy	61 248	Stock Option (Right to Buy)

INSIDER POWER
57.41
Last 54 transactions
Buy: 749 992 \| Sell: 831 346

PharmaCyte Biotech, Inc. Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

PharmaCyte Biotech, Inc. Finanzdaten

Annual	2023
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$-0.220

FY	2023
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$-0.220

FY	2022
Umsatz:	$0
Bruttogewinn:	$0 (0.00 %)
EPS:	$-0.260

FY	2021
Umsatz:	$0.00
Bruttogewinn:	$0.00 (0.00 %)
EPS:	$-2.45

Financial Reports:

No articles found.

PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.